GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xiangxue Pharmaceutical Co Ltd (SZSE:300147) » Definitions » Long-Term Debt

Xiangxue Pharmaceutical Co (SZSE:300147) Long-Term Debt : ¥201 Mil (As of Mar. 2025)


View and export this data going back to 2010. Start your Free Trial

What is Xiangxue Pharmaceutical Co Long-Term Debt?

Xiangxue Pharmaceutical Co's Long-Term Debt for the quarter that ended in Mar. 2025 was ¥201 Mil.

Xiangxue Pharmaceutical Co's quarterly Long-Term Debt declined from Sep. 2024 (¥578 Mil) to Dec. 2024 (¥571 Mil) and declined from Dec. 2024 (¥571 Mil) to Mar. 2025 (¥201 Mil).

Xiangxue Pharmaceutical Co's annual Long-Term Debt increased from Dec. 2022 (¥427 Mil) to Dec. 2023 (¥556 Mil) and increased from Dec. 2023 (¥556 Mil) to Dec. 2024 (¥571 Mil).

Xiangxue Pharmaceutical Co Long-Term Debt Historical Data

The historical data trend for Xiangxue Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xiangxue Pharmaceutical Co Long-Term Debt Chart

Xiangxue Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 946.92 528.92 426.93 556.00 570.64

Xiangxue Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 547.27 492.89 578.49 570.64 201.46

Xiangxue Pharmaceutical Co  (SZSE:300147) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Xiangxue Pharmaceutical Co Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Xiangxue Pharmaceutical Co's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Xiangxue Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xiangxue Pharmaceutical Co Ltd (SZSE:300147) » Definitions » Long-Term Debt
Comparable Companies
SHSE:688302 SZSE:300871 SHSE:688202 SHSE:603896 SZSE:300858 SZSE:301230 SHSE:688767 SHSE:688399 SHSE:688253 SZSE:300583 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
No 2 Jinfeng Road , Science City, Guangzhou Economic and Technological Development Z, Guangzhou, CHN, 510663
Website
http://www.xphcn.com
Xiangxue Pharmaceutical Co Ltd is a China-based company engages in the manufacture and distribution of pharmaceutical products. Its diversified healthcare portfolio includes Chinese Herbal Slices, TCM, Life Science, Biomedical Engineering health solutions (food and beverage), healthcare supplements and so on.
Executives
Huang Wei Hua Supervisors
Tan Wen Hui Director
Kang Zhi Ying Executives
Ceng Lun Executives
Liu Yan Executives
Lu Feng Executives
Xu Li Secretary, Director
Mo Zi Yu Supervisors
Mai Zhen Jiang Supervisors
Wang Yong Hui Directors, executives
He Tao Executives
Fang Wei Min Supervisors
Huang Bin Directors, Directors, and Executives
Wu Jun Executives
Chen Wen Jin Executives

Xiangxue Pharmaceutical Co Headlines

No Headlines